RNA vaccine takes on malaria in first human trial

NCT ID NCT05581641

Completed ⭐️ VACCINE ⭐️ Sponsor: BioNTech SE Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This early-stage trial tested an experimental RNA vaccine called BNT165b1 in 60 healthy adults to see if it is safe and triggers an immune response against malaria. The vaccine uses messenger RNA to teach the body to recognize a key malaria protein. The study was completed and focused on finding a safe dose, not yet on proving the vaccine prevents malaria.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BNT165b1 RNA vaccine
What this could lead to: If successful, this could lead to a new type of vaccine to protect against malaria, a major global health threat.
What could go wrong: This is a very early Phase 1 trial with only 60 participants, focused on safety and immune response, not yet on preventing malaria. Many vaccines fail in later stages.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALARIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Plasmodium falciparum malaria malaria prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALARIA

Contacts and locations

Locations

Alliance for Multispecialty Research, LLC

Tempe, Arizona, 85281, United States
Alliance for Multispecialty Research, LLC

Las Vegas, Nevada, 89119, United States
Alliance for Multispecialty Research, LLC

Knoxville, Tennessee, 37909, United States
Clinical Trials of Texas, Inc.

San Antonio, Texas, 78229, United States
University of Maryland, Center for Vaccine Development

Baltimore, Maryland, 21201, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.